Jilin Province Huinan Changlong Bio-pharmacy Company Limited (8049.HK)
HKD 1.56
(-3.11%)
HKD 1.56
(-3.11%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -271.73 Million CNY | -140.05% |
| 2022 | -113.2 Million CNY | -106.22% |
| 2021 | -54.89 Million CNY | -114.29% |
| 2020 | -25.61 Million CNY | 81.03% |
| 2019 | -135.03 Million CNY | 13.43% |
| 2018 | -155.99 Million CNY | -45.16% |
| 2017 | -107.45 Million CNY | 29.2% |
| 2016 | -151.76 Million CNY | 13.53% |
| 2015 | -175.51 Million CNY | -44.47% |
| 2014 | -121.48 Million CNY | -97.45% |
| 2013 | -61.52 Million CNY | 21.04% |
| 2012 | -77.92 Million CNY | -23.71% |
| 2011 | -62.98 Million CNY | 30.68% |
| 2010 | -90.86 Million CNY | -148.96% |
| 2009 | -36.5 Million CNY | 12.76% |
| 2008 | -41.84 Million CNY | -44.26% |
| 2007 | -29 Million CNY | -21.35% |
| 2006 | -23.9 Million CNY | -129.64% |
| 2005 | -10.4 Million CNY | -149.71% |
| 2004 | -4.16 Million CNY | 20.81% |
| 2003 | -5.26 Million CNY | 79.92% |
| 2002 | -26.21 Million CNY | 52.72% |
| 2001 | -55.43 Million CNY | -1887.75% |
| 2000 | 3.1 Million CNY | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -258.47 Million CNY | 4.88% |
| 2024 Q2 | -258.47 Million CNY | 0.0% |
| 2023 Q2 | -91.06 Million CNY | -108.67% |
| 2023 Q3 | 1.21 Billion CNY | 1437.07% |
| 2023 Q1 | 1.04 Billion CNY | 1027.38% |
| 2023 FY | -271.73 Million CNY | -140.05% |
| 2023 Q4 | -271.73 Million CNY | -122.32% |
| 2022 FY | -113.2 Million CNY | -106.22% |
| 2022 Q4 | -113.2 Million CNY | -130.06% |
| 2022 Q3 | 376.62 Million CNY | 554.54% |
| 2022 Q1 | 300.25 Million CNY | 646.98% |
| 2022 Q2 | -82.85 Million CNY | -127.6% |
| 2021 FY | -54.89 Million CNY | -114.29% |
| 2021 Q2 | -18.36 Million CNY | -106.48% |
| 2021 Q1 | 283.54 Million CNY | 1206.88% |
| 2021 Q4 | -54.89 Million CNY | 0.0% |
| 2020 FY | -25.61 Million CNY | 81.03% |
| 2020 Q1 | 863.85 Million CNY | 739.7% |
| 2020 Q2 | -704.99 Million CNY | -181.61% |
| 2020 Q4 | -25.61 Million CNY | 0.0% |
| 2019 Q4 | -135.03 Million CNY | 0.0% |
| 2019 Q2 | -146.26 Million CNY | 0.0% |
| 2019 FY | -135.03 Million CNY | 13.43% |
| 2018 Q1 | 599.06 Million CNY | 657.48% |
| 2018 Q4 | -155.99 Million CNY | 0.0% |
| 2018 Q2 | -156.6 Million CNY | -126.14% |
| 2018 FY | -155.99 Million CNY | -45.16% |
| 2017 Q2 | -197.65 Million CNY | -142.85% |
| 2017 Q4 | -107.45 Million CNY | 0.0% |
| 2017 FY | -107.45 Million CNY | 29.2% |
| 2017 Q1 | 461.23 Million CNY | 403.91% |
| 2016 Q1 | 340.76 Million CNY | 294.15% |
| 2016 FY | -151.76 Million CNY | 13.53% |
| 2016 Q4 | -151.76 Million CNY | 0.0% |
| 2016 Q2 | -138.87 Million CNY | -140.75% |
| 2015 Q1 | 161 Million CNY | 232.53% |
| 2015 Q2 | -157.96 Million CNY | -198.11% |
| 2015 Q4 | -175.51 Million CNY | 0.0% |
| 2015 FY | -175.51 Million CNY | -44.47% |
| 2014 Q4 | -121.48 Million CNY | 0.0% |
| 2014 FY | -121.48 Million CNY | -97.45% |
| 2014 Q2 | -80.78 Million CNY | -179.12% |
| 2014 Q1 | 102.1 Million CNY | 265.95% |
| 2013 Q1 | 91.18 Million CNY | 217.02% |
| 2013 Q4 | -61.52 Million CNY | 0.0% |
| 2013 Q2 | -63.7 Million CNY | -169.86% |
| 2013 FY | -61.52 Million CNY | 21.04% |
| 2012 Q4 | -77.92 Million CNY | 0.0% |
| 2012 Q2 | -79.32 Million CNY | 0.0% |
| 2012 FY | -77.92 Million CNY | -23.71% |
| 2011 Q4 | -62.98 Million CNY | 0.0% |
| 2011 FY | -62.98 Million CNY | 30.68% |
| 2011 Q2 | -51.17 Million CNY | 0.0% |
| 2010 Q4 | -90.86 Million CNY | 0.0% |
| 2010 Q2 | -43.28 Million CNY | 0.0% |
| 2010 FY | -90.86 Million CNY | -148.96% |
| 2009 FY | -36.5 Million CNY | 12.76% |
| 2008 FY | -41.84 Million CNY | -44.26% |
| 2007 FY | -29 Million CNY | -21.35% |
| 2006 FY | -23.9 Million CNY | -129.64% |
| 2005 FY | -10.4 Million CNY | -149.71% |
| 2004 FY | -4.16 Million CNY | 20.81% |
| 2003 FY | -5.26 Million CNY | 79.92% |
| 2002 FY | -26.21 Million CNY | 52.72% |
| 2001 FY | -55.43 Million CNY | -1887.75% |
| 2000 FY | 3.1 Million CNY | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Pak Fah Yeow International Limited | -258.7 Million HKD | -5.038% |
| Grand Pharmaceutical Group Limited | 2.03 Billion HKD | 113.374% |
| Extrawell Pharmaceutical Holdings Limited | 5.94 Million HKD | 4671.618% |
| Wai Yuen Tong Medicine Holdings Limited | 301.53 Million HKD | 190.118% |
| Qianhai Health Holdings Limited | -19.03 Million HKD | -1327.34% |
| Lee's Pharmaceutical Holdings Limited | 30.94 Million HKD | 978.044% |
| Essex Bio-Technology Limited | -219.22 Million HKD | -23.951% |
| Tongfang Kontafarma Holdings Limited | 256.16 Million HKD | 206.079% |
| PuraPharm Corporation Limited | 377.54 Million HKD | 171.974% |
| SSY Group Limited | 1.71 Billion HKD | 115.858% |
| JBM (Healthcare) Limited | -7.39 Million HKD | -3572.618% |
| Jacobson Pharma Corporation Limited | 337.44 Million HKD | 180.529% |
| China Resources Pharmaceutical Group Limited | 50.97 Billion HKD | 100.533% |